[go: up one dir, main page]

PE20100684A1 - Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh - Google Patents

Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh

Info

Publication number
PE20100684A1
PE20100684A1 PE2010000354A PE2010000354A PE20100684A1 PE 20100684 A1 PE20100684 A1 PE 20100684A1 PE 2010000354 A PE2010000354 A PE 2010000354A PE 2010000354 A PE2010000354 A PE 2010000354A PE 20100684 A1 PE20100684 A1 PE 20100684A1
Authority
PE
Peru
Prior art keywords
variable region
asparagine
antibody containing
amyloid antibody
antibody
Prior art date
Application number
PE2010000354A
Other languages
English (en)
Inventor
Karl Weyer
Manfred Brockhaus
Bernd Bohrmann
Hans Koll
Andreas Schaubmar
Kurt Lang
Diana Schuhbauer
Hansruedi Loetscher
Walter Huber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20100684A1 publication Critical patent/PE20100684A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA MOLECULA DE ANTICUERPO CUYO SITIO DE UNION AL ANTIGENO COMPRENDE UNA ASPARAGINA (Asn) GLICOSILADA EN LA REGION VARIABLE DE LA CADENA PESADA (VH) EN LA REGION CDR2, EN DONDE LA ASPARAGINA GLICOSILADA SE ENCUENTRA EN LA POSICION 52 DE LA SEQ ID NO: 2 O EN LA POSICION 52 DE LA SEQ ID NO: 6. DICHO ANTICUERPO ES MONOGLICOSILADO O BIGLICOSILADO Y ES CAPAZ DE RECONOCER EL PEPTIDO B-A4 / AB4. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DEL ANTICUERPO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A AMILOIDOGENESIS O FORMACION DE PLACAS DE AMILOIDE TALES COMO LA ENFERMEDAD DE ALZHEIMER, SINDROME DE DOWN, ENFERMEDAD DE PARKINSON, ESCLEROSIS LATERAL AMIOTROFICA (ALS)
PE2010000354A 2005-12-12 2006-12-11 Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh PE20100684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05027090 2005-12-12

Publications (1)

Publication Number Publication Date
PE20100684A1 true PE20100684A1 (es) 2010-10-04

Family

ID=37745986

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2006001587A PE20071002A1 (es) 2005-12-12 2006-12-11 Anticuerpo anti b4-amilode que contiene asparagina glicosilada en la region variable de vh
PE2010000560A PE20100748A1 (es) 2005-12-12 2006-12-11 Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh
PE2010000354A PE20100684A1 (es) 2005-12-12 2006-12-11 Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2006001587A PE20071002A1 (es) 2005-12-12 2006-12-11 Anticuerpo anti b4-amilode que contiene asparagina glicosilada en la region variable de vh
PE2010000560A PE20100748A1 (es) 2005-12-12 2006-12-11 Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh

Country Status (33)

Country Link
US (2) US8906370B2 (es)
EP (2) EP1960428B1 (es)
JP (1) JP5145241B2 (es)
KR (2) KR101401159B1 (es)
CN (2) CN102659943B (es)
AR (1) AR057233A1 (es)
AT (1) ATE517923T1 (es)
AU (1) AU2006326301B2 (es)
BR (1) BRPI0619605B8 (es)
CA (1) CA2632828C (es)
CR (1) CR10000A (es)
CY (1) CY1114783T1 (es)
DK (1) DK1960428T3 (es)
DO (1) DOP2006000278A (es)
EC (1) ECSP088524A (es)
ES (1) ES2368591T3 (es)
IL (1) IL191004A (es)
JO (1) JO2824B1 (es)
MA (1) MA30038B1 (es)
MY (1) MY155286A (es)
NO (1) NO346105B1 (es)
NZ (1) NZ568241A (es)
PE (3) PE20071002A1 (es)
PL (1) PL1960428T3 (es)
PT (1) PT1960428E (es)
RS (1) RS52004B (es)
RU (1) RU2438706C2 (es)
SI (1) SI1960428T1 (es)
TW (1) TWI382990B (es)
UA (1) UA99097C2 (es)
UY (1) UY30003A1 (es)
WO (1) WO2007068429A1 (es)
ZA (1) ZA200805038B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007068429A1 (en) * 2005-12-12 2007-06-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2007331712A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
HRP20180565T1 (hr) * 2007-06-29 2018-05-04 F. Hoffmann - La Roche Ag Mutant teškog lanca koji dovodi do poboljšane proizvodnje imunoglobulina
DK3216802T3 (da) * 2007-08-20 2021-01-04 Glaxo Group Ltd Produktionsfremgangsmåde
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
JP5624535B2 (ja) * 2008-05-02 2014-11-12 シアトル ジェネティクス，インコーポレーテッド 低いコアフコシル化を有する抗体及び抗体誘導体を調製するための方法並びに組成物
US20140213465A1 (en) * 2011-12-02 2014-07-31 Plaxgen, Inc. Plaque array methods and compositions for forming and detecting plaques
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
EP2519537A4 (en) * 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
JP6431372B2 (ja) * 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド 抗体製剤および方法
AU2013229613B2 (en) 2012-03-08 2015-07-30 F. Hoffmann-La Roche Ag Abeta antibody formulation
SI2890712T1 (sl) * 2012-08-29 2019-08-30 F. Hoffmann-La Roche Ag Prenašalec prek krvno-možganske pregrade
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
US9790276B2 (en) 2012-12-18 2017-10-17 The Rockefeller University Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
AR094780A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies ANTICUERPOS ANTI-TNF-a ALTAMENTE GALACTOSILADOS Y SUS USOS
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
JP6086566B2 (ja) 2013-11-22 2017-03-01 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
UA123053C2 (uk) 2015-06-24 2021-02-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
MX388197B (es) * 2015-08-21 2025-03-19 Hoffmann La Roche Método para la reducción de proteínas de células hospederas en cromatografía de afinidad.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
HUE057085T2 (hu) * 2015-10-16 2022-04-28 Hoffmann La Roche Egy rendszer mûködtetésére szolgáló eljárás és egy rendszer
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
US20190114464A1 (en) * 2016-03-10 2019-04-18 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN116333108A (zh) 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US20200113854A1 (en) * 2017-05-30 2020-04-16 Morinaga Milk Industry Co., Ltd. Composition for Improving Brain Function
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CA3070085A1 (en) 2017-07-18 2019-01-24 Promis Neurosciences Inc. Antibodies to amyloid beta
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
JP2023549809A (ja) * 2020-11-16 2023-11-29 エフ． ホフマン－ラ ロシュ アーゲー Ｆａｂ高マンノースグリコフォーム
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114720543A (zh) * 2022-04-06 2022-07-08 苏州大学 一种基于固相糖蛋白t抗原糖肽富集和酶切分析的方法
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
CN117783359B (zh) * 2023-12-28 2024-12-31 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) * 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP1308461A3 (en) 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
AU5976996A (en) * 1995-06-06 1996-12-24 Stemcell Therapeutics L.L.C. Glycoprotein gp105 on bl3 hematopoietic stem cells
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1161449B1 (en) * 1999-03-04 2007-07-04 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
DK1409654T3 (da) 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
EP1209969A2 (en) 1999-08-31 2002-06-05 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0016022A (pt) 1999-11-29 2002-08-06 Neurochem Inc Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
TR200202799T3 (tr) 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005501220A (ja) 2000-12-19 2005-01-13 パラチン テクノロジーズ インク． ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別
WO2002088307A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
AU2002258808A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US7771722B2 (en) * 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
EP1432444A4 (en) * 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2007068429A1 (en) * 2005-12-12 2007-06-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
AU2007331712A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation

Also Published As

Publication number Publication date
BRPI0619605B8 (pt) 2021-05-25
US20090252724A1 (en) 2009-10-08
ES2368591T3 (es) 2011-11-18
KR20080077132A (ko) 2008-08-21
AU2006326301B2 (en) 2011-04-21
SI1960428T1 (sl) 2011-10-28
US20150165022A1 (en) 2015-06-18
ZA200805038B (en) 2009-06-24
CN101351476A (zh) 2009-01-21
AU2006326301A1 (en) 2007-06-21
MY155286A (en) 2015-09-30
UY30003A1 (es) 2007-08-31
CA2632828C (en) 2012-07-10
KR20120089483A (ko) 2012-08-10
EP2377886A1 (en) 2011-10-19
NZ568241A (en) 2011-08-26
RU2008128138A (ru) 2010-01-20
NO346105B1 (no) 2022-02-21
UA99097C2 (ru) 2012-07-25
MA30038B1 (fr) 2008-12-01
PT1960428E (pt) 2011-10-07
RS52004B (sr) 2012-04-30
HK1176075A1 (en) 2013-07-19
HK1130066A1 (en) 2009-12-18
CY1114783T1 (el) 2016-12-14
CR10000A (es) 2008-07-29
BRPI0619605B1 (pt) 2019-08-13
RU2438706C2 (ru) 2012-01-10
TWI382990B (zh) 2013-01-21
ECSP088524A (es) 2008-07-30
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
BRPI0619605A2 (pt) 2011-10-11
IL191004A (en) 2013-08-29
EP1960428B1 (en) 2011-07-27
PL1960428T3 (pl) 2012-02-29
JP2009520691A (ja) 2009-05-28
CN102659943A (zh) 2012-09-12
CN101351476B (zh) 2013-04-03
CN102659943B (zh) 2015-07-01
AR057233A1 (es) 2007-11-21
WO2007068429A1 (en) 2007-06-21
EP1960428A1 (en) 2008-08-27
NO20082874L (no) 2008-08-28
KR101401159B1 (ko) 2014-05-29
DOP2006000278A (es) 2007-07-15
TW200736273A (en) 2007-10-01
DK1960428T3 (da) 2011-08-22
ATE517923T1 (de) 2011-08-15
JO2824B1 (en) 2014-09-15
PE20100748A1 (es) 2010-11-12
PE20071002A1 (es) 2007-11-19
JP5145241B2 (ja) 2013-02-13
US9272031B2 (en) 2016-03-01
US8906370B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
PE20100684A1 (es) Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh
PE20081634A1 (es) Fab ab pegilado
CR20150016A (es) Anticuerpo monoclonal
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
CL2012001817A1 (es) Anticuerpo monoclonal que reconoce epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos, particularmente a los peptidos abeta amiloides solubles polimericos y peptidos abeta amiloides oligomericos; polinucleotidos que codifican dicho anticuerpo; composicion terapeutica que comprende el anticuerpo; uso del anticuerpo para tratar enfermedades y trastornos causados o asociados a las proteinas amiloides (div. sol. 1742-2008).
ATE414106T1 (de) Pegylierte single-domain-antikörper (dab)
EP4574166A3 (en) Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
EA201190018A1 (ru) Миостатинсвязывающие белки
CL2013000390A1 (es) Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer.
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
EA201100694A1 (ru) Антитело к cd38 человека и его применение
DOP2010000097A (es) Anticuerpos especificos para la forma de protofibrillas de la proteina beta-amiloide
AR085198A1 (es) Composicion farmaceutica
JO3188B1 (ar) بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل
WO2007098607A8 (en) Methods and compositions to treat and detect misfolded-sod1 mediated diseases
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CL2016000215A1 (es) Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).
PE20140448A1 (es) Moleculas de union biespecificas que se unen a vegf y ang2
BRPI0619357A8 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
NZ601117A (en) Biparatopic abeta binding polypeptides
WO2014031694A3 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
BR112012007563A2 (pt) peptídeos sintéticos antagonistas de miostatina
DK1786442T3 (da) Behandling af neurodegenerative sygdomme under anvendelse af DEGS-inhibitorer

Legal Events

Date Code Title Description
FC Refusal